
|Videos|April 19, 2022
Introduction: A 52-Year-Old Woman with Intermediate-Risk Primary Myelofibrosis
Author(s)Srdan Verstovsek, MD, PhD
Srdan Verstovsek, MD, PhD, comments on the patient profile and discusses the typical presentation of patients with myelofibrosis (MF).
Advertisement
Episodes in this series

Now Playing
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
The Targeted Pulse: New Standards in Myeloma, Melanoma, and More
2
FDA Accepts BLA for Ivonescimab in Pretreated EGFR-Mutated NSCLC
3
Onvansertib Triplet Shows Dose-Dependent Frontline Benefit in RAS-Mutant Metastatic CRC
4
Pembrolizumab/Lenvatinib Show Efficacy, Safety in Clear Cell Gyn Cancers
5

















